Jahn Ferenc Del-Pesti Korhaz Es Rendelointezet
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Jahn Ferenc Del-Pesti Korhaz Es Rendelointezet, clinical research in cardiovascular medicine focuses on major conditions such as dyslipidemia, atrial fibrillation, and heart failure. The trials are designed to test new treatment approaches, reduce the risk of serious heart and circulation events, and improve long-term disease control.
- Evaluating therapies for primary prevention of atherosclerotic cardiovascular disease
- Studying treatment options to prevent stroke and systemic embolism in atrial fibrillation
- Assessing new approaches for heart failure with preserved or mildly reduced ejection fraction
- Testing medicines aimed at lowering LDL cholesterol and reducing major cardiovascular risk
These studies reflect a strong focus on improving prevention and treatment for patients at elevated risk of cardiovascular events, while also exploring better ways to manage inflammation-related heart disease.
Eye Diseases
Research in ophthalmology at this site includes studies for macular edema secondary to retinal vein occlusion. The main goal is to find more effective ways to preserve and improve vision in people affected by retinal swelling.
- Testing a new treatment strategy for macular edema linked to retinal vein occlusion
- Comparing approaches to improve visual acuity and eye health outcomes
The eye research program is centered on evaluating whether newer treatment options can offer meaningful vision benefits while maintaining safety and tolerability for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 10 therapeutic areas and 15 of 86 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 86 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Colorado Prevention Center2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Bayer AG4trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Jahn Ferenc Del-Pesti Korhaz Es Rendelointezet
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 86 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 4 | Unknown | 2023-09-13 | 2026-06-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.